Bioactive compounds from phytoplankton containing glycosidic residue for apoptosis and cancer treatment

• US 9,217,741 B2
• Filed: 11/05/2010
• Issued: 12/22/2015
• Est. Priority Date: 11/05/2009
• Status: Expired due to Fees

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University, Woods Hole Oceanographic Institution
• Inventors: Bidle, Kay Daniel, Vardi, Assaf, Van Mooy, Benjamin A. S., Fredricks, Helen F., Haramaty, Liti
• Primary Examiner(s): Ware, Debbie K
• Application Number:
  US12/940,927
• Publication Number:
  US 20110129851A1
• Time in Patent Office: 1,873 Days
• US Class Current: 1/1
• CPC Class Codes: G01N 2510/00 Detection of programmed cell death, i.e. apoptosis
• CPC Class Codes: G01N 33/5044 involving specific cell types
• CPC Class Codes: G01N 33/5097 involving plant cells immunoassays of plant cells G01N33/56961

Abstract

Phytoplankton represent a potential source of bioactive compounds. The present disclosure provides, inter alia, methods for identifying glycerolipids and apoptosis-inducing sphingosine-like lipids from virally-infected phytoplankton.

Claims

1. A pharmaceutical composition comprising a compound having a structure of formula (I)

2. A method for inducing apoptosis in a cancer cell, a lymphocyte that recognizes self-peptides, or a virally-infected cell, comprising contacting the cell or lymphocyte with a pharmaceutical composition according to claim 1.

3. A method for treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 1.

4. A pharmaceutical composition comprising a glycerolipid having a mass spectra pattern as shown in FIG. 9A or 9B and a pharmaceutically acceptable carrier or diluent.

5. A method for inducing apoptosis in a cancer cell, a lymphocyte that recognizes self-peptides, or a virally-infected cell, comprising contacting the cell or lymphocyte with a pharmaceutical composition according to claim 4.

6. A method for treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 4.

7. A pharmaceutical composition comprising a substantially purified bioactive lipid expressed to a greater degree in virally infected than in non-virally infected phytoplankton, of which said bioactive lipid induces apoptosis of phytoplankton in an assay, said assay comprising the steps of:

(a) contacting the phytoplankton with the bioactive lipid; and

(b) assaying the phytoplankton for apoptosis-associated activity in the presence of the bioactive lipid;

wherein apoptosis-induced activity in the phytoplankton indicates that the bioactive lipid induces apoptosis of phytoplankton;

and wherein said bioactive lipid has a structure of Formula (I);

8. The bioactive lipid containing composition according to claim 7, wherein the bioactive lipid is capable of inducing apoptosis in a cancer cell, a lymphocyte that recognizes self-peptides, or a virally-infected cell.

9. A method for inducing apoptosis in a cancer cell, a lymphocyte that recognizes self-peptides, or a virally-infected cell, comprising contacting the cell or lymphocyte with a pharmaceutical composition according to claim 7.

10. A method for treating cancer in a patient, comprising administering to the patient a pharmaceutical composition according to claim 7.